Novel targeted therapies of T cell lymphomas
Open Access
- 31 December 2020
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 13 (1) , 1-38
Abstract
T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are effective in B cell lymphomas, but in TCL are associated with a high failure rate and frequent relapses. Furthermore, in contrast to B cell NHL, in which substantial clinical progress has been made with the introduction of monoclonal antibodies, no comparable advances have been seen in TCL. To change this situation and improve the prognosis in TCL, new gene-targeted therapies must be developed. This is now possible due to enormous progress that has been made in the last years in the understanding of the biology and molecular pathogenesis of TCL, which enables the implementation of the research findings in clinical practice. In this review, we present new therapies and current clinical and preclinical trials on targeted treatments for TCL using histone deacetylase inhibitors (HDACi), antibodies, chimeric antigen receptor T cells (CARTs), phosphatidylinositol 3-kinase inhibitors (PI3Ki), anaplastic lymphoma kinase inhibitors (ALKi), and antibiotics, used alone or in combinations. The recent clinical success of ALKi and conjugated anti-CD30 antibody (brentuximab-vedotin) suggests that novel therapies for TCL can significantly improve outcomes when properly targeted.Keywords
Funding Information
- Narodowe Centrum Badań i Rozwoju (WPC/BCL/2019)
- Narodowe Centrum Nauki (DEC-2013/09/B/NZ1/01867, 2019/35/D/NZ5/00407)
This publication has 214 references indexed in Scilit:
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptorsJournal of Clinical Investigation, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Critical Role for TSLC1 Expression in the Growth and Organ Infiltration of Adult T-Cell Leukemia Cells In VivoJournal of Virology, 2008
- Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabLeukemia Research, 2008
- Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantationClinical and Experimental Immunology, 2008
- Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBlood, 2007
- Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxinsBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006